Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Groupement des Hôpitaux de l'Institut Catholique de Lille | OTHER |
| Universitaire Ziekenhuizen KU Leuven | OTHER |
| Rennes University Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
The objective of this project is to verify the validity and determine the clinimetric properties after translation and adaptation into French of the Trunk Impairment Scale (TIS), a scale for measuring trunk control and seated balance.
The research will be conducted in two distinct phases :
The role of the evaluators (between D2 and D3) will be divided so that the TIS assessments and those related to construct validity are carried out by three different therapists in order to maintain the evaluators' "blindness" regarding the patient's functional level.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| TIS | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Evaluation by the TIS | Other | The participant will be evaluated using the TIS on two consecutive days. An evaluation will be conducted by two different evaluators. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Content validity | he validity of the content is evaluated at four levels, described in detail in the methodology section of the translation and cross-cultural adaptation phase: By the reading committee (for the translation, reconciliation, and back-translation phases) By a group of professional experts in the field (to approve or not the pre-final versions) By comparing the items of the original TIS with its back-translation, by Prof. Verheyden and his team By a cognitive interview with patients, to assess the proper understanding of each item. | Through Phase 1 completion (up to 6 months) |
| Measure | Description | Time Frame |
|---|---|---|
| intra-examiner reliability | The TIS is administered several times by the same examiner at different moments. It is also considered as "the degree to which patients' scores remain the same during repeated measurements under several conditions" over time (test-retest), by the same person at different moments (intra-examiner), and at the same moment by different observers (inter-examiner). Two indices are used:
|
Not provided
Inclusion criteria (Phase 1):
Inclusion criteria (Phase 2):
Exclusion Criteria (Phase 1):
Exclusion Criteria (Phase 2):
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jean-Philippe Plouzennec, Kinésithérapeute | Contact | +33 2.97.82.62.93 | jean-philippe.plouzennec@vyv3.fr | |
| Longuet Charline, CRA | Contact | +33297826293 | charline.longuet@vyv3.fr |
| Name | Affiliation | Role |
|---|---|---|
| Plouzennec Jean-Philippe, Physiotherapist | Centre de Kerpape | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre de Kerpape | Recruiting | Ploemeur | Please Choose... | 56270 | France |
Not provided
| ID | Term |
|---|---|
| D020521 | Stroke |
| D002546 | Ischemic Attack, Transient |
| ID | Term |
|---|---|
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Through Phase 2 completion (up to 21 months) |
| inter-examiner reliability | The TIS is administered at the same moment by different observers. It is also considered as "the degree to which patients' scores remain the same during repeated measurements under several conditions" over time (test-retest), by the same person at different moments (intra-examiner), and at the same moment by different observers (inter-examiner). Two indices are used:
| Through Phase 2 completion (up to 21 months) |
| Internal Consistency | To assess the internal consistency of behavioral and clinical items. Internal consistency reflects the interrelationship between items and indicates whether each item measures the same underlying construct. Cronbach's alpha coefficient will be calculated. Values > 0.7 indicate good internal consistency; values close to 1 may indicate redundancy. | Through Phase 2 completion (up to 21 months) |
| Standard Error of Measurement | To calculate the Standard Error of Measurement (SEM) for behavioral and clinical scores. SEM quantifies the variability of repeated measurements and reflects measurement error. It can be influenced by the examiner, the measurement tool, or the patient. SEM is used to compute the Minimum Detectable Change (MDC). | Through Phase 2 completion (up to 21 months) |
| Minimum Detectable Change | To determine the Minimum Detectable Change (MDC) for behavioral and clinical measures. MDC represents the smallest change beyond measurement error that reflects a true change in the patient's condition. It will be calculated using : MDC = SEM * 1.96 * √2 | Through Phase 2 completion (up to 21 months) |
| Convergent validity | Convergent validity will be evaluated by comparing the TIS with the following scales: • NIHSS (National Institutes of Health Stroke Scale) : This scale measures the intensity and severity of neurological signs caused by stroke, and monitors their evolution. • Barthel Index : An index assessing functional independence across 10 categories by rating the amount of assistance required by the patient in each domain. Demeurisse Motor Index : This scale assesses motor control of the upper and lower limbs after a stroke, only on the affected side.
| Through Phase 2 completion (up to 21 months) |
| Known-groups discrimination | Known-groups discrimination will be performed by: A subgroup analysis comparing patients who are able to stand independently, those who can walk, those who can walk quickly, those who perform transfers independently, and non-walkers. These categories may be established based on the results of the previously mentioned tests. | Through Phase 2 completion (up to 21 months) |
| Concurrent validity | The concurrent validity of the TIS will be assessed by comparing its scores with established measures of postural control and trunk stability. PASS (36 pts): Evaluates balance in supine, sitting, and standing positions, including transitions. TCT (100 pts): Assesses four trunk movements: rolling toward affected/unaffected side, balancing sitting at edge of bed, and sitting up from lying. EPA (4 pts): Evaluates seated postural balance with or without support, considering induced or self-generated imbalance. Results reported as Pearson or Spearman correlations with TIS scores. | Through Phase 2 completion (up to 21 months) |
| Ceiling and Floor Effects | It demonstrates the difficulty of the tool in measuring the patient's abilities below (floor) or above (ceiling) a certain level. It shows the inadequacy of the tool for the situation of the patient being assessed. To highlight these effects, a large number of patients is required. The distribution of results becomes asymmetrical if one of these effects is observed. | Through Phase 2 completion (up to 21 months) |
| Missing data | The absence of responses to an item will be counted. The relevance of the item may be questioned if it accounts for too many missing responses. | Through Phase 2 completion (up to 21 months) |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D002545 | Brain Ischemia |